Trial Profile
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen Administered Subcutaneously to Japanese Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Mipomersen (Primary)
- Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
- Focus Pharmacokinetics
- Sponsors Ionis Pharmaceuticals; Kastle Therapeutics
- 13 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Feb 2011 New trial record